SNOG-FIBTRA SYMPOSIUM 2022
Multidisciplinary Neuro-Oncology
Updated 10.5.2022
Radisson Blu Seaside Hotel, Helsinki, 19-21 May 2022
Thursday 19 May 2022
8:00-9:30 Arrival and registration
Opening of the symposium
9:30 Opening words
Adjunct Professor Kirsi Granberg, President of SNOG and Chair of FiBTRA, Tampere University, Tampere, Finland
Session 1 Brain tumors among us today
Chair: Adjunct Professor Hanna Mäenpää and Professor Roger Henriksson
9:40 Are brain tumors becoming more common?
Adjunct professor Nea Malila, Director of the Finnish Cancer Registry, Cancer Society of Finland, Finland
10:10 Risk factors for brain tumors – current evidence
Professor Anssi Auvinen, Tampere University, Tampere, Finland
10:40 Elderly and glioma – Nordic perspective
Associate Professor Miikka Korja, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
11:10 Sponsor presentation by 10x Genomics, Zeiss and Lioness Therapeutics
Luncheon with Novocure
Moderator: Professor Roger Henriksson
11:20 Picking up the lunch
11:35 TTFields: Transitioning cancer treatment – The journey from research to guideline recommendation
Introduction –
Professor Roger Henriksson, Umeå University, Umeå, Sweden
Preclincial overview
Doctor Moshe Giladi, Novocure, Haifa, Israel
Clinical experience
Professor NaTosha Gatson, Banner MD Anderson Cancer Center (BMDACC) and University of Arizona
School of Medical, Phoenix, Arizona and Geisinger Commonwealth School of Medicine (GCSoM), Scranton, Pennsylvania, USA
Discussion
12:20-12:30 Break
Session 2 Heterogeneity and evolution of brain tumors
Chair: Professor Pirjo Laakkonen and Adjunct Professor Kirsi Granberg
12:30 Malignant networks in the brain (and how to target them)
Professor Frank Winkler, University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany
13:15 Mutational processes shaping the evolution of brain tumours
Doctor Joachim Weischenfeldt, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
Abstract talks
13:45 Neural-network based deconstruction of glioblastoma developmental plasticity at a single cell resolution
Doctor Yizhou Hu, Karolinska Institutet, Stockholm, Sweden
14:00 Gatekeeper inactivation drives tumor progression to secondary glioblastoma
Anja Hartewig, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland
14:15 Oncogenic enhancer-promoter interactions in medulloblastoma
Eduardo Dias, University of Copenhagen, Copenhagen, Denmark
14:30-15:00 Coffee break -visit poster presenters (Group 1) and sponsors
Session 3 Up-to-date treatment modalities
Chair: Adjunct Professor Hanna Mäenpää and Doctor Matti Seppälä
15:00 Boron Neutron Capture Therapy (BNCT)
Doctor Hanna Koivunoro, Neutron Therapeutics Finland, Helsinki, Finland
15:15 Tumor treating fields (TTFields)
Doctor Sara Kinhult, Lund University, Lund, Sweden
15:30 Protons or photons in IDH-mutated grade II and III diffuse gliomas?
Doctor Petter Brandal, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
Abstract talks
15:45 CCNU/temozolomide versus standard temozolomide radiochemotherapy +/- Tumor Treating Fields for patients with MGMT promotor methylated IDHwt glioblastoma. Phase 3 study
Doctor Annika Malmström, Linköping University, Linköping, Sweden
16:00 Triplet kinase-phosphatase targeting to overcome kinase inhibitor tolerance in brain tumor cells
Doctor Oxana Denisova, Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
16:15 Orthogonal targeting of KDM6A/B and HDACs mediates potent therapeutic effects in IDH1-mutant glioma
Associate Professor Tugba Bagci-Onder, Koç University, Istanbul, Turkey
16:30 The DCCC Brain Tumor Center. National Research Center for Target therapy
Professor Hans Skovgaard Poulsen, The DCCC Brain Tumor Center, Copenhagen University Hospital, Copenhagen, Denmark
16:45 Updates from Nordic countries
Denmark – Professor Hans Skovgaard Poulsen, Copenhagen University Hospital, Copenhagen
Norway – Doctor Petter Brandal, The Norwegian Radium Hospital, Oslo University Hospital, Oslo
Sweden – Professor Roger Henriksson, Umeå University, Umeå
Finland – Doctor Matti Seppälä, Hospital District of Helsinki and Uusimaa (HUS), Helsinki
17:15 Sponsor presentations by Tenboron, Cancer Foundation Finland, and Johnson&Johnson
17:25 Day wrap-up and discussion
18:00- Reception
Friday 20 May 2022
Session 4 Biomarkers in brain tumors
Chair: Professor Hans Skovgaard Poulsen and Doctor Petter Brandal
9:00 Longitudinal evolution of glioma in adult patients
Professor Roel Verhaak, Jackson Laboratory, Farmington, CT, USA and Amsterdam University Medical Center, Amsterdam, Netherlands
Abstract talks
9:45 Integrative DNA methylation analysis of pediatric brain tumors reveals tumor type-specific developmental trajectories and epigenetic signatures of malignancy
Joonas Uusi-Mäkelä, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland
10:00 EGFR expression and non-methylated MGMT predicts distant recurrence in glioblastoma patients treated with standard therapy
Doctor Thomas Urup, The DCCC Brain Tumor Center, Rigshospitalet, Copenhagen, Denmark
10:15 Accurate classification of central nervous system tumors based on DNA methylation data from a reduced set of genomic regions
Doctor Alejandra Rodríguez Martínez, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland
10:30 Sponsor presentations by Orion and NanoString Technologies
10:40-11:00 Coffee break and visit sponsors
Session 5 Neurosurgery
Chair: Doctor Matti Seppälä and Adjunct Professor Hanna Mäenpää
11:00 Intra-operative monitoring in glioma surgery
Doctor Päivi Koroknay-Pal, Helsinki University Hospital, Helsinki, Finland
11:30 Aspects on the surgery of low grade gliomas
Professor Ole Solheim, St. Olavs Hospital, Trondheim, Norway
12:00 Laser ablation in neuro-oncology
Doctor Jiri Bartek, Karolinska University Hospital, Stockholm, Sweden
Abstract talks
12:15 Integrated PDX analysis, single-cell profiling and computational modeling to reveal route-specific mechanisms of GBM invasion
Doctor Milena Doroszko, Uppsala University, Uppsala, Sweden
12:30 A Personalized BRAF Mutant Glioblastoma Model using Human ex-vivo Cortical Cultures
Junyi Zhang, University of Freiburg, Germany
12:45-14:00 Lunch and visit sponsors and posters
13:30-14:00 Visit poster presenters (Group 1)
Session 6 Signaling in brain tumors
Chair: Professor Jukka Westermarck and Professor Matti Nykter
14:00 Generation of brain cancer avatars through genome engineering of human iPSCs
Professor Frank Furnari, University of California San Diego (UCSD) and Ludwig Institute for Cancer Research, San Diego, USA
14:45 Novel insight into gliomas: from biology to treatment.
Adjunct professor Simone Niclou, Luxembourg Institute of Health, Luxembourg and University of Bergen, Bergen, Norway
Abstract talks
15:15 Vessel co-option and glioblastoma resistance to therapy are induced by cell state transition and senescence
Doctor Giorgio Seano, Institut Curie Research Center, Paris-Orsay, France
15:30 Spatially resolved glioblastoma Invadome identifies neurodevelopmental pathway reprogramming and therapeutic opportunities
Doctor Vadim Le Joncour, University of Helsinki, Helsinki, Finland
15:45-16:15 Coffee break -visit poster presenters (Group 2) and sponsors
Session 7 Why targeted therapies fail in clinical trials?
Chair: Professor Roger Henriksson and Professor Jukka Westermarck
16:15 Panel discussion
Professor Frank Furnari, Adjunct Professor Simone Niclou, Professor Roel Verhaak and Professor Monika Hegi
17:15-17:30 Day wrap-up and discussion
19:00-Symposium dinner
Saturday 21 May 2022
Session 8 Brain tumor microenvironment and immunology
Chair: Adjunct Professor Kirsi Granberg and Doctor Jiri Bartek
9:00 Cellular plasticity and interactions within the glioma microenvironment
Doctor Itay Tirosh, Weizmann Institute of Science, Rehovot, Israel
Abstract talks
9:45 Single-cell analysis of tumor-associated microglia and macrophages from human glioblastoma
Doctor Rikke Sick Andersen, Odense University Hospital, Odense, Denmark
10:00 Immunophenotyping reveals complex immune cell phenotypes in brain tumour microenvironment, including unreported myeloid subsets
Ismaïl Hermelo, Tampere University and Tays Cancer Center, Tampere University Hospital, Tampere, Finland
10:15-10:30 Coffee break -visit sponsors
Session 9 Patient stratification and treatment
Chair: Doctor Petter Brandal and Professor Hans Skovgaard Poulsen
10:30 Grade 2 and 3 IDH mutant gliomas: the state of the art in 2022
Professor Martin van den Bent, ErasmusMC Cancer Institute, Rotterdam, the Netherlands
11:00 Epigenetic vulnerabilities – markers and treatment opportunities
Professor Monika Hegi, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
Abstract talks
11:30 The Role of Aging in Glioblastoma
Doctor Vidhya Madapusi Ravi, University of Freiburg, Germany
11:45 Gliotarget: a Danish nationwide phase I/II platform trial focusing on individualized targeted treatment for newly diagnosed glioblastoma patients based on genomic profiling.
Vincent Nicolay Fougner, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
12:00 -13:15 Lunch and visit sponsors and posters
12:45-13:15 Visit poster presenters (Group 2)
Session 10 Brain metastases
Chair: Professor Pirjo Laakkonen and Professor Matti Nykter
13:15 Strategies to challenge brain metastasis lethality in mice and human
Doctor Manuel Valiente, CNIO, Madrid, Spain
Abstract talks
13:45 Brain metastases NAVIGATOR as a novel theranostic tool
Abiodun Ayo, University of Helsinki, Helsinki, Finland
14:00 Method for intraoperative detection of IDH mutation in gliomas with differential mobility spectrometry
Ilkka Haapala, Tampere University Hospital, Tampere, Finland
14:15 Closing words
Host of the next SNOG meeting and
Adjunct professor Kirsi Granberg, President of SNOG and Chair of FiBTRA, Tampere University, Tampere,
Finland
14:30 End of the symposium
Program (pdf)
Please note, that the program might still change due to exceptional circumstances. Latest version and updates are presented here on the symposium web pages.